End of the Transition Period for companies subject to Cosmetics Regulation in Switzerland
In June 2014, Switzerland launched Project LARGO and changed its regulation in order to harmonize it with the European Union (EU) and simplify trade procedures. Several transition periods were granted. Presently, the obligation to provide a safety assessment report for each cosmetic product, create a Product Information File, and to follow Good Manufacturing Practices (GMP) has already come into force.


Switzerland is a member of the European Free Trade Association (EFTA) but it is not a participant of the Agreement on the European Economic Area (EEA). In Switzerland, cosmetic products need to be in compliance with the Federal Office for Food Safety and Veterinary Affairs (OSAV).

Project LARGO (2014) was developed as an effort to adjust the legal framework and had as main goals: guarantee food safety (top priority and to match EU safety level); break down trade barriers with the EU; and create conditions to participate in safety systems run by the EU (RASFF, RAPEX, EFSA). Harmonization with the EU Cosmetic Regulation was the central objective of Swiss Regulation changes.

On May 1st 2017, ordinance on foodstuffs and consumer goods and ordinance on cosmetic products entered into force. These ordinances set up some requirements for cosmetic products similar to the ones present in the European Regulation.

According to the Federal Act on Foodstuffs and Utility Articles (Foodstuffs Act, FSA, 817.0) cosmetics are considered utility articles (and not foodstuffs) which, when used as normally intended, externally come into contact with the body, teeth or mucous membranes. The same act says that it must be possible to trace cosmetics at all levels of production, processing and distribution phases.


The Safety Assessment Report necessary for cosmetic products must obey to the same standards in Switzerland and the EU (European Cosmetics Regulation (EC) No. 1223/22009). It needs to have a part A (information regarding the product and formula) and a part B (safety assessment details such as warnings, conclusions and reasoning, and information about the safety assessor who performed it).

The Federal Council may stipulate further requirements for cosmetic products and recommends following Good Manufacturing Practices (GMP). Cosmetic products must comply with the lists of regulated substances and have a Product Information File (PIF). Advertising, labelling and forbidding deception are also regulated and included in the ordinance. Moreover, if the final formulation or ingredients of cosmetics have been tested in animals, the Federal Council may restrict or prohibit the placing on the market of such cosmetics (in order to comply with foodstuff legislation).

Ingredients present in cosmetic products made available on the Swiss market need to comply with the Annexes of the European Regulation (EC) No. 1223/2009. Nevertheless, the Federal Department of Home Affairs may establish exemptions.

Despite the similarities, Swiss regulation is still different from the EU. For example, artisanal cosmetic products sold locally (which are not intended for children) do not need to have a PIF. Although the address of the EU Responsible Person (RP) may be put on the label, the responsibility to ensure compliance with Swiss Regulation is attributed to the manufacturer/importer (which needs to be designated for each cosmetic product made available on the market and they may not delegate this responsibility to an EU RP or any other legal person abroad).

As part of the harmonization with EU Cosmetic Regulation, several deadlines were set. The obligation to provide a safety assessment report for each cosmetic product, create a Product Information File, and to follow Good Manufacturing Practices (GMP), has come into force since the 30th of April, 2021. This date represented the last deadline for the harmonization process.

With the LARGO Project and the harmonization of its Regulation with the European Union, Switzerland aims to achieve the same level of protection for consumers as seen in the EU. Cosmetic products made available in the Swiss market must comply with the lists of regulated substances, labelling, and the obligations defined in the EU Cosmetic Regulation. Switzerland also follows the same 6 common criteria set out in the Commission Regulation (EU) No 655/2013 regarding the justification of cosmetic claims.

Compliance with different Regulations can be a challenge and it is important to be up to date. Critical Catalyst is available to help you, wherever you wish to place your cosmetic products. For more information bout Switzerland requirements and other enquiries, feel free to contact us at info@criticalcatalyst.com.


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Federal Assembly of the Swiss Confederation – Federal Act on Foodstuffs and Utility Articles (Foodstuffs Act, FSA) of 20 June 2014 (Status as of 1 May 2021)
  3. Swiss Federal Council – Ordinance on the Use of Swiss Indications of Source for Cosmetic Products of 23 November 2016 (Status as of 1 January 2017)
  4. Conseil Fédéral Suisse – Ordonnance sur les denrées alimentaires et les objets usuels, du 16 décembre 2016 (Etat le 1er juillet 2020)  


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »